Periodontal ligament stem cells as a promising therapeutic target for neural damage

Fariba Mohebichamkhorami1, Roya Fattahi1, Zahra Niknam2, Morteza Aliashrafi3, Sahar Khakpour Naeimi4, Samira Gilanchi2 and Hakimeh Zali1,5*

Abstract

Background: The damaged neuronal cells of adult mammalian lack the regenerative ability to replace the neuronal connections. Periodontal ligament stem cells (PDLSCs) are the promising source for neuroregenerative applications that can improve the injured microenvironment of the damaged neural system. They provide neuronal progenitors and neurotrophic, anti-apoptotic and anti-inflammatory factors. In this study, we aimed to comprehensively explore the various neuronal differentiation potentials of PDLSCs for application in neural regeneration therapy.

Main text: PDLSCs have superior potential to differentiate into various neural-like cells through a dedifferentiation stage followed by differentiation process without need for cell division. Diverse combination of nutritional factors can be used to induce the PDLSCs toward neural lineage. PDLSCs when coupled with biomaterials could have significant implications for neural tissue repair. PDLSCs can be a new clinical research target for Alzheimer’s disease treatment, multiple sclerosis and cerebral ischemia. Moreover, PDLSCs have beneficial effects on retinal ganglion cell regeneration and photoreceptor survival. PDLSCs can be a great source for the repair of injured peripheral nerve through the expression of several neural growth factors and differentiation into Schwann cells.

Conclusion: In conclusion, these cells are an appealing source for utilizing in clinical treatment of the neuropathological disorders. Although significant in vitro and in vivo investigations were carried out in order for neural differentiation evaluation of these cells into diverse types of neurons, more preclinical and clinical studies are needed to elucidate their therapeutic potential for neural diseases.

Keywords: Periodontal ligament stem cells, Neural regeneration, Neural differentiation, Neurotrophic factors, Apoptosis, Inflammation

Introduction

The central nervous system (CNS) and the peripheral nervous system (PNS) are parts of the nervous system. The brain and spinal cord make up the CNS, whereas cranial and spinal nerves, as well as their associated ganglia, constitute the PNS. The PNS has a built-in ability to regenerate and repair itself, whereas the CNS is essentially incapable of self-repair. Furthermore, depending on the characteristics and type of damage, the inherent regenerating ability is limited through injury itself [1].

In neural injuries, the damaged neural cells such as neurons and glial cells of adult mammalian lack the regenerative ability to replace the neuronal connections. This is due to the limited ability of neuronal progenitors to regenerate functional neuronal cells and inhibition of
neural regeneration by the local injured microenvironment, especially in the glial scar [2].

One of the main formidable reasons for the limited success of pharmacotherapeutic strategies in neural damages is the microenvironment of the injury site with many molecular growth inhibitors that are hostile to any neuroregenerative therapy and function restoring of nerve fibers. It leads to the incapability of the damaged nerves to regrow and develop new synaptic connections. Targeting these inhibitors could be an efficient approach to overcome the permanent stopping of nerve growth [3].

The development of more precise therapies focused at specific molecular targets linked with a specific disease or injury of the nervous system has resulted from advances in neuroregenerative research. Due to several pathological injury processes and mechanisms, any neuroregenerative approach that focuses on just one of the events or mechanisms will not probably lead to a considerable therapeutic effect on neural injuries. The reasons for the limited therapeutic options are mainly because of both the extracellular and intracellular components of the nervous system that inhibits regeneration. To bridge the short-term requirements and revive immediate function of the nervous system, changes in plasticity and neuroregeneration firstly occur at the regional level. The lengthy and more permanent process of restoring function occurs at cellular level and promotes one or more of the restorative mechanisms which may improve neurological damages [4, 5].

Neuroregenerative medicine (NRM) is a growing field with the goal of neurogenesis, angiogenesis and synaptic plasticity [5] through replacement of lost cells and tissues and restoration of normal function [2]. Scientists are optimistic about the potentials of NRM to lead to providing novel approaches for the treatment of neural diseases and answer the ethical questions about their clinical applications [6].

NRM uses stem cells as a promising tool that make up for the scarcity of cell alternatives. Transplanted stem cells can improve the microenvironment in the injured site of the neural system and provide neuronal progenitors [7]; then, they help to slow or repair the deterioration related to degenerative or traumatic neural diseases and trigger a great effort in the field of preclinical and clinical neural research [8].

Mesenchymal stem cells (MSCs) have potential to integrate into host neuronal networks and renew functional neural connections. They can restore synaptic transmitter secretion, modulate the plasticity of damaged host tissues as well as release growth and neurotrophic factors with ability to promote cell survival [9]. In addition, MSCs have been found to diminish inflammation in vivo by suppressing pro-inflammatory cytokines and increasing anti-inflammatory cytokines and antigen-specific T-regulatory cells [10]. Researchers suggested that MSCs can cross the blood–brain barrier (BBB) [11], and this ability is the main reason for the treatment potential in neural diseases like cerebral ischemic diseases or spinal cord injuries [12, 13].

The oral cavity as an available source of MSCs includes two kinds of cells. Nondental oral MSCs which comprise periodontal ligament stem cells (PDLSCs), gingival MSCs (GMSCs), and dental follicle stem cells (DFSC) and the dental MSCs which consist of stem cells from apical papilla (SCAP), dental pulp stem cells (DPSCs) and stem cells from exfoliated deciduous teeth (SHED) [7].

Oral stem cells are rather accessible and show broad differentiation potential and high plasticity; hence, they can make autologous cell transplantation possible [8]. Moreover, they have advantages such as a higher proliferation rate and potential of immunosuppression [14, 15]; therefore, they are an excellent cell source in order for allogeneic transplantation.

They originate from cranial neural crest-derived ectomesenchymal cells (CNCCs); thus, they are capable of differentiation into neural cells in order for the reconstruction of central nervous system tissues. These cells express neural progenitors markers, including nestin, Pax6, Tuj1 and p75/NGFR, and have a more favorable neurotrophic secretome [16].

**Periodontal ligament-derived MSCs**

PDL is the connective tissue that connects the root of the tooth to the alveolar bone socket, and it is derived from embryonic CNCCs. It includes bone and cementum cells and a mix of fibroblasts, mesenchymal and undifferentiated cells, all of which are seated on a hydrated fibrillar extracellular substance rich in collagen [17]. Human periodontal ligament stem cells (hPDLSCs) derived from PDL. PDLSCs are an ethical and accessible source of cells. These are an ample source of undifferentiated cells with a doubling rate of 22 h from periodontal ligament (PDL) with low rate of immunogenicity and can be transplanted without need for pre-differentiation, and they have the potential for the off-the-shelf product [2].

Periodontal ligament stem cells (PDLSCs) contain 95% of mesenchymal stem cells and 5% of neural crest stem cells [18]. These cells have the ability to grow clonally and express MSCs markers (vimentin, STRO-1, CD90, scleraxis, CD44), markers of embryonic stem cells (c-Myc, SSEA4, KIf4, Oct4, Nanog and Sox2) and neural crest cells markers (Sox10, nestin, Snail, Slug, Sox10 p75 and Tuj1). These markers are considered as hallmarks of multipotency that highlight the differentiation capacity of PDLCs into various cell types, such as chondrogenic,
cardiomyogenic, osteogenic and neurogenic lineages [19–21]. (Fig. 1).

PDLSCs possess cell replacement potential without tumorigenicity in cultured PDL cells. PDLSCs can exert an immunomodulatory effect via inflammatory cell recruitment [22, 23]. Different spectra of neurotrophic factors secretion were indicated by human PDLSCs such as BDNF, NGF, CNTF, bFGF, NT-3, VEGFA, IGF-1, and GDNF. Transplantation of different source of hPDLSCs like autologous and allogeneic sources can be promising paracrine-mediated and cell-free therapy for neural damage. The cell surface markers and differentiation potentiality of PDLSCs are similar to that of BMSCs and DPSCs [24], although it is demonstrated that the pluripotency and regenerative capacity of PDLSCs decrease with age [25].

Isolation and characterization of PDLSCs

**PDLSCs isolation**

PDLSCs isolation was described for the first time by Seo BM [26] and Trubiani [27]. These stem cells can be isolated with different techniques and expanded in a xeno-free medium with no alteration in morphological properties, their normal karyotype, and markers related to pluripotency. PDLSCs can be easily harvested from periodontal tissue during the noninvasive procedure [28, 29]. Different methods that are described to this date have some technical problems, but a simplified and highly replicable method is required [30].

Periodontal ligament biopsies can be obtained from root planning and dental scaling procedure. The first and second premolar teeth are suitable for the purpose of PDLSCs isolation. Teeth must be healthy with no sign of caries, periapical lesion, periodontal disease or gingivitis. Teeth are transferred in the cell culture medium supplemented with 1% antibiotic at 4 °C. In all seeding techniques, complete Dulbecco’s modified Eagle medium (DMEM) (supplemented with L-glutamine, 1% antibiotic, 10% of FBS) is used in standard culture conditions (37 °C with 5% CO2). The cells are isolated with two different methods through enzymatic digestion with type 1 collagenase or trypsin/EDTA and mechanical disaggregation and explant culture [30].

For enzymatic digestion, tissue is digested during 1 h at 37 °C in 500 µl type I collagenase at a concentration of 0.5 mg/ml or 500 µl of 0.25% trypsin with 0.1% EDTA [31]. At 10-min intervals, the sample is shaken every 30 s. The enzyme is inactivated with complete DMEM. Filtration of suspension is carried out with a 70-µm-diameter mesh to prepare a single-cell suspension, and

---

**Fig. 1** Schematic illustration of periodontal ligament stem cells characteristics. Neural stem cells (NSCs). Mesenchymal stem cells (MSCs). Embryonic stem cells (ESCs). Created with BioRender.com
centrifugation is performed at 1200 RPM/10 m. The supernatant is removed, and sediments tissue is resuspended in complete DMEM. 300–500 μL of suspension is seeded in 6-well plates, and the culture medium is changed every 3 days. The advantages of this method are higher viability of samples during transportation with DMEM, and also, conducted rinses in this method are efficient. Disadvantages of this technique are sample filtering and prolonged time for enzymatic digestion [30, 32].

For explant, cultured tissue fragments of approximately 1 mm diameter are minced and seeded on a culture plate or flasks with a minimum amount of complete DMEM. Explants are placed in the incubator under standard conditions, and it takes 6–8 h to adhere to the culture plate. After cell attachment, 500 μL of complete cell culture media is added. After 72 h, to discard floating tissue fragments, medium is changed. The advantage of this technique is that the use of explants provides high expectancy to access primary tissue; the disadvantage is very prolonged time for explant adhesion and washes with deficient time [30, 33].

**PDLSCs characterization**

**Cell migration assessment**  After the cells reached confluency, a lesion that causes continuity loss between PDLSCs is performed along the culture. The culture is monitored with photographs taken at different time points (12, 24, 48 and 72 h). After 12 h of lesion onset, cell migration toward the scratched area can be observed. Cell numbers increase after 24 h, and at 48 h after lesion onset, cells are in semi-confluence, and after 72 h, cells totally can cover the area [34].

**Flow cytometric analysis for cell surface markers**  Multiparametric flow cytometry can analyze the expression of cell surface markers of PDLSCs. PDLSCs from passage 4 are used for this experiment. Trypsinized cells are counted using a hemocytometer, adjusted to the concentration of 0.7 – 10⁶ cells in 700 ml PBS, and equally divided into seven separate flow tubes. Cells (1 × 10⁶) are incubated for 45 min at 4 °C with the specific antibodies conjugated with fluorescein isothiocyanate (FITC). Cells are stained using antibodies against CD105, CD73, CD166, CD90, CD34, CD45, CD13, CD29, CD44, CD146, HLA-DR, OCT3/4, Sox2 and Nestin, SSEA4 intracellular antigens, p75, SOX10, CD49, SLACS and neural crest-related markers to study the cell surface characteristics [32, 35, 36]. The CLPP, NQO1, SCOT1, DDAH1 and a new isoform of TBB5 proteins that are related to the cell cycle regulation and homing, stress reaction and detoxification can be studied in PDLSCs [37]. After incubation with each antibody, the cells are washed adequately and characterized with a flow cytometer. PDLSCs are negative for the hematopoietic markers, which are essential for defining mesenchymal cells.

**Trilineage differentiation of the PDLSCs**  PDLSCs with upon 80% confluency are trypsinized and counted. A total 5.1 – 10⁵ cells are seeded into wells (4.3 – 10³ cells per cm²). After cells reached 80% confluency, media is changed from complete culture media to specific trilineage differentiation media (adipogenic, osteogenic and chondrogenic media). The differentiation media is changed every 4 days, and the cells are fixed, rinsed and stained on day 28; then, the adipogenic, osteogenic and chondrogenic differentiation potential of PDLSCs can be analyzed by staining with Oil Red O, Alizarin Red and Alcian blue stains, respectively. The cells are left for 30 min and 50 min at room temperature for staining with Alizarin Red/Alcian blue and Oil Red O, respectively. Following staining, the wells are washed with water, and water is added to each well to allow for visual inspection during imaging and prevent the cells from drying [32].

**Gene analysis with reverse transcriptase-polymerase chain reaction (RT-PCR)**  The total RNA is extracted from the isolated PDLSCs and used for the synthesis of cDNAs through RT-PCR. The expression profile of pluripotency markers (including Oct4A, Sox2 and NANOG) is evaluated and read by gel electrophoresis. The GAPDH gene is used as the control in the gel. The expression of GAPDH and Sox2 in PDLSCs is more intense than that of Oct4A and NANOG [32, 34].

**Neural differentiation potential of PDLSCs**  Since PDLSCs have the same embryologic origin of the neural crest with many mature neural cell types, they are less lineage-divergent to neural cells compared to many other stem cells types; therefore, these options make PDLSCs promising for neuroregenerative applications [2, 7, 38].

PDLSCs mediated neural regeneration through different mechanisms (Fig. 2) including migrating to the defect site and replacing the damaged cells [39] or recruiting the endogenous neural stem cells in injured site [40]. Moreover, they exert paracrine effect via increased expression of neurotrophic factors under the induction of neural injury environment and lead to stimulation of the neural progenitor cells to survive and differentiate [33, 41, 42]. They promote axon regeneration and synapse formation. Also, they can suppress cell apoptosis which is the major reason of neuronal loss in spinal cord injury (SCI) and Alzheimer’s disease (AD) [33, 40]. In addition, they inhibit
the release of TNFα and upregulate the expression level of anti-inflammatory cytokines [43, 44].

In this study, various neuronal differentiation potentials of PDLSCs for application in neural regeneration therapy are summarized. An additional file shows this in more detail (see Table 1).

Widera et al. [45] reported that PDLSCs are capable of differentiation into neural cells and glial cell lineages [45]. PDLSCs have potential to differentiate into neurofilament positive neuron-like cells, cyclic nucleotide phosphodiesterase-positive oligodendrocyte-like cells, and astrocyte-like cells with positive GFAP [46]. PDLSCs can successfully differentiate into neural-like cells in 8–16 days [2].

The sequence of the maturation of the neural-like cells from stem cells does not always need cell division. In vitro neurogenesis from hPDLSCs does not result in cell proliferation; it shows micronuclei movement and transient lobulation of cell nuclei, which is strikingly comparable to primary neuronal cultures and neurogenic niches in adult mouse brain [47].

Furthermore, there is a theory that MSCs transdifferentiate directly into neural cells, but this interpretation has been questioned. The fundamental criticism against this method is that the MSCs quickly adopt the morphologies of neuron-like cells by retracting their cytoplasm rather than actively extending neurites. Time-lapse microscopy was used to examine the order of biological cascades during neural differentiation processes of hPDLSCs, human bone marrow mesenchymal stem cells (hBMSCs) and hDPSCs. It was demonstrated that these cells shrink substantially and via extension of neurites they change their shape to neuron-like cells; the important point is that a dedifferentiation stage occurs prior to differentiation into neural phenotypes [48].

It is studied that growth factors have positive effects on the neural differentiation of PDLSCs. The nutritional factors like basic fibroblast growth factor (bFGF), nerve growth factor (NGF), L-glutamine, insulin-like growth factor-1 (IGF-1) and epidermal growth factor (EGF) are leading to induction of PDLSCs differentiation into neuronal lineage [49]. NGF is an effective inducing factor. Preconditioning of PDLSCs with dimethyl sulfoxide leads to better results [50].

Through using a combination of bFGF and EGF, PDLSCs can be induced into neural-like cells. Morphological changes to both neuronal and glial phenotypes were evident after this neuro-induction treatment and a significant increase was detected in b-tubulin III and nestin expressions, as well as positive staining of GFAP. Moreover, neural connections have been demonstrated with positive staining of synaptophysin in immunohistochemical analysis. The whole-cell patch clamping verified the outward and inward currents via voltage-gated sodium channels. In this process, PDLSCs differentiated into the neural cells at different rates because CD133
| Cells                  | Induction                  | Effects                                                                 | Delivery method                                                                 | Target molecules                                                                 | Type of study | Ref |
|------------------------|----------------------------|------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------------------------|---------------|-----|
| PDLSCs                 | With bFGF + EGF            | Differentiated to neuronal and glial cells; patch clamp showed outward and inward currents | –                                                                              | βIII-tubulin↑ nestin↑ GFAP↑ synaptophysin↑ SOX1↑ NEFM↑ Noggin↓                    | In vitro     | [2] |
| PDLSCs                 | With bFGF and EGF          | Differentiated to neural crest stem cells; glutamate-induced calcium responses | –                                                                              | βIII-tubulin↑ NeuN↑ neurofilament↑ S100↑ neuron-specific enolase↑ GFAP↑ mIIR-132↑ ZEB2↓ | In vitro     | [51]|
| Xeno-free hPDLSCs      |                            | Differentiated to a very small and rounded cell body with thin neurite-like projections | –                                                                              |                                                                  | In vitro     | [13, 64]|
| PDLSCs+GMSCs           | With NGF                   | Several islands of dense structures; positive for neurogenic specific markers, candidates for nerve tissue engineering | Encapsulated in alginate/hyaluronic acid hydrogel                              | βIII-tubulin↑ GFAP↑ VAMP2↑                                                   | In vitro     | [57]|
| PDLSCs                 | Co-culturing PDLSCs with OA-induced SH-SYSY cells | Recovery of cytoskeleton structure, cell shape and viability; apoptosis of okadac acid-induced SH-SYSY cells ptau | –                                                                              | ↓ apoptosis related molecules                                                   | In vitro     | [59]|
| PDLSCs                 |                            | ↓ Inflammation and demyelination in the spinal cord in multiple sclerosis (MS) in animal model | Single-dose intravenous injection to the tail vein                              | ↓ inflammation and demyelination molecules, neurotrophic factors↑            | In vivo     | [80]|
| DPSCs and PDLSCs       |                            | Migrate toward injured areas and differentiate into neuron-like cells, in vivo in rat model of cerebral ischemia | Direct administration                                                            | ↓ Notch pathway molecules↑ Wnt signaling pathway molecules↑ Wnt3α↑ endolase↑ tubulin↑ Thy-1↑ Jagged-1↓ | In vivo     | [61]|
| PDLSC-CM               | PDLSCs obtained from RR-MS patients | Reduce inflammatory damage in the animal model of MS (in EAE mice) | Systemic administration                                                         | TGF-β↑ IL-10↑                                                                | In vivo     | [62]|
| PDLCS-CM               | under hypoxic conditions   | Pathology-independent ability of PDLSCs niche↑ functionality of the PI3K/Akt/mTOR axis modulate markers of oxidative stress, autophagy and apoptosis | Injection of vesicles or conditioned medium to MS animal model                  | ↓ pro-inflammatory and ↑ anti-inflammatory cytokines beclin-1↑ LC3↑ Interferon-γ↓ IL-17↓ BDNF↑ | In vitro in vivo | [62, 65, 66]|
| hPDLSCs-CM             |                            | Enhanced level of NFκB and TLR4 and decreased amount of cleaved caspase-3 in lipopolysaccharide-stimulated NSC34 mouse motoneurons | –                                                                              | ↑ NFκB and TLR4 ↓ cleaved caspase-3                                             | In vitro     | [67]|
| PDLSCs                 | PDLSCs are in contact with retinal ganglion cells (RGCs) in retinal explant culture | Neuroprotective effect and enhanced neurite regeneration in retinal tissue without macrophage recruitment | –                                                                              | BDNF↑                                                            | In vitro     | [68, 69]|
| PDLSCs                 |                            | Electrically functional RGC survival and axonal regeneration in vivo in rat model of optic nerve injury | Intravitreal transplantation of PDLSCs                                         |                                                                  | In vivo     | [70]|

Table 1 Potential of periodontal ligament stem cells in neural regeneration
| Cells            | Induction                                                                 | Effects                                                                 | Delivery method | Target molecules | Type of study | Ref  |
|------------------|---------------------------------------------------------------------------|-------------------------------------------------------------------------|-----------------|------------------|---------------|------|
| PDLSCs           | Differentiation into RGCs expression of ATOH7, POL4F2, β-III tubulin, MAP2, TAU, NEUROD1 and SIX3, formed synapses spontaneous electrical activities glutamate-induced calcium responses | –                                                                       | VEGF↑ PTEN↑     | In vitro        | [69]           |
| PDLSCs           | Induction through chemically inhibiting Wnt and BMP signaling on Matrigel-coated surface | Differentiation into photoreceptor rosette-like outgrowth and excitatory glutamate response (Nrl+ rhodopsin+ Pax6+) | –               | In vitro         | [68, 71]       |
| PDLSCs           | Erk1/2 signaling                                                         | Differentiation into Schwann cells                                       | P75↑ S100↑ GFAP↑ P0↑ krox-20↑ Oct-6↑ | In vitro        | [17, 77, 78]   |
| PDLSCs           | Indirect co-culturing of heterogenous Schwann cells and PDLSCs (allogenic neurotrophic factors released by Schwann cells) | Presenting Schwann cell phenotype                                        | –               | In vitro         | [75]           |
| PDLSCs           | Sandblasted and acid-etched (SA) titanium surface                        | Schwann-like cells highest expression of SC markers and proteins on the SA titanium surface | –               | In vitro         | [79]           |
| CM of the SCAPs, PDLSCs, and DPSCs | Induction of the cells with mixture of growth factors, induction of SH-SYSY cells with CM of the stimulated cells (in vitro) | BDNF↑ GDNF↑ in injured area, enhanced neurite outgrowth in SH-SYSY cells in vitro, reduced the expression of caspase-3, higher level of neuronal markers in PDLSCs and SCAP in rat sciatic nerve injury model | BDNF↑ GDNF↑ caspase-3↓ | In vivo         | [41, 80, 82]   |
| PDLSCs           | Recovery of sensory function ↑myelinated axons and retrograde labeled sensory neurons crush-injured left mental nerve in rats | Injected into the crush-injured left mental nerve                         | ↑NGF receptor    | In vivo          | [80, 81]       |
(human stem cell marker) did not show statistically significant change and SOX1 and NEFM noticeably but not statistically increased compared to control. Noggin that commonly has a function in neural development significantly decreased most likely due to increasing in matured cells [2].

Neural crest stem cells (NCSCs) differentiated from hPDLSCs were induced through differentiation medium containing bFGF and EGF for 24 days. The cells showed glutamate-induced calcium responses and time-dependent increase in markers of neuronal and glial cells including βIII-tubulin, NeuN, neurofilament, S100, neuron-specific enolase and GFAP. The process of neuronal differentiation of human NCSCs is aided by miRNA regulation. After differentiation, sixty human miRNAs have been upregulated and nineteen of them downregulated. miR-132 overexpression in NCSCs led to the downregulation of ZEB2 as a negative regulator of neuronal differentiation. The gene ontology analyses demonstrated that target genes of miR-132 are often involved in the neural differentiation processes such as axon guidance and neuron projection; therefore, miR-132 can help to neural differentiation of NCSCs [51].

Xeno-free hPDLSCs due to neural crest origin express neural markers as nestin and GAP-43 spontaneously. GAP-43 is present in the periodontal Ruffini endings that play a substantial role in nerve repair and development [52]. GAP-43 involves in mechanisms control branching and pathfinding of the glial cells [53, 54]. The PKCα/GAP-43 nuclear signaling pathway controls neural differentiation of PDLSCs. A cytoskeleton rearrangement occurs during the process and shows a rounded and small cell body with thin projections like neurites [55, 56].

PDLSCs and GMSCs were encapsulated in alginate/hyaluronic acid hydrogel with sustained releasing of NGF. The encapsulated PDLSCs exhibited a higher level of neural genes expressions such as βIII-tubulin and GFAP and more numbers of cell colonies compared to GMSCs; however, both cells exhibited higher β-tubulin III expression than bone marrow MSCs. In all treated groups, VAMP2 (a synaptic protein) was positive. It was demonstrated that the elasticity of the hydrogel and biochemical microenvironment can impact on the rate of differentiation and proliferation of the encapsulated cells. The lowest level of elasticity led to the highest level of β-tubulin III expression. Moreover, the inductive signals can show the road of differentiation process. Seeded hydrogels were subcutaneously implanted in immunocompromised mice. Immunofluorescence and histochemical staining after 4 weeks of implantation showed several islands of dense structures and positive for neurogenic specific markers inside the cell-seeded hydrogels [57].

Central nervous system treatment

The regenerative potential of PDLSCs in CNS diseases has been proven [51]. PDLSC engraftment and differentiation into the neural cells in adult mouse brain provided strong evidence for the utilization of these cells in order for cell therapy of neurodegenerative diseases [58]. (Fig. 3).

Effects of PDLSCs on the morphology and function of okadaic acid (OA)-induced SH-SY5Y cells as models of AD were investigated in vitro. PDLSCs are capable of regenerating tissues that have been damaged by AD characterized by deposited tau protein (pTau). 24-h co-culturing PDLSCs with OA-induced SH-SY5Y cells confirmed recovery of cytoskeleton structure and cell shape as well as cell viability compared to control. Apoptosis levels in SH-SY5Y cells induced by OA were decreased, and pTau expression was reduced [59]. Therefore, PDLSCs can be a new clinical research target for the AD treatment. Further studies about the effect of PDLSCs on the molecular and behavioral changes in AD are required.

Single-dose intravenous injection of 10⁶ hPDLSCs per 150 μl into the tail vein of the multiple sclerosis (MS) animal model at the beginning of the disease can decrease the signs of inflammation and demyelination in the spinal cord of the animals. It is due to the suppression of inflammatory mediators and the increased production of neurotrophic factors [60].

The DPSCs’ and PDLSCs’ differentiation into neuron-like cells was performed, and their therapeutic effects were investigated after administration in rat model of cerebral ischemia. Results exhibited that the expressions of Wnt3a, enolase and tubulin were noticeably enhanced and the expression of Jagged-1 was markedly decreased after neurogenic induction in both groups of cells but with more pronounced change in PDLSCs. PDLSCs showed a higher differentiation rate and expression of the Thy-1 (a neuronal differentiation marker). The Notch inhibition and Wnt signaling activation were detected in this process; therefore, these pathways have a regulatory role in the neural differentiation of the cells. In immunofluorescence studies, the spatial distribution and survival of labeled cells in the brain of rats were detected and a significantly higher red fluorescence signal was emitted from PDLSC-treated rats. It was more around the periphery of the ischemic area than in non-infarcted areas on the contralateral side. In vivo, PDLSCs can pass from the blood–brain barrier more efficiently and migrate to ischemic areas faster than DPSCs. The size of the infarcted area was significantly smaller in PDLSCs treated group. This finding indicates that the neural differentiation potential and in vivo therapeutic effect of PDLSCs are more evident than DPSCs [61].
The conditioned medium of PDLSCs can reduce inflammatory damage in the animal model of MS [62]. Also, purified extracellular vesicles from PDLSCs have a similar effect. A mixed population of shedding vesicles and exosomes which contain anti-inflammatory cytokines TGF-β and IL-10 stained positive for surface mesenchymal antigens CD29 and CD90. Moreover, the secretome content of MSCs as a reservoir of regenerating neuronal factors is a key regulator of the neurogenic niche [62, 63].

Conditioned medium (CM) of the cells is useful in enhancing long-term neuronal regeneration in spinal cord injury [64]. The injection of vesicles or PDLSCs conditioned medium (PDLSCs-CM) of patients with relapsing-remitting MS to mouse model of MS showed the same result; the functional and pathology-independent ability of PDLSCs niche was demonstrated that can be applied for several other inflammatory and neurodegenerative diseases. PDLSCs-CM obtained from MS patients under hypoxic conditions when injected (1300 μG of hPDLSCs-CM/mouse) in mouse with autoimmune encephalomyelitis (EAE) as MS animal model leads to reduced pro-inflammatory and induced anti-inflammatory cytokines [62]. It can potentially modulate markers of oxidative stress, autophagy and apoptosis through increasing the expression of beclin-1 and LC3 (principal markers of autophagy) and reducing the interferon-γ and IL-17 expression (65). PDLSC secretome can reduce oxidative stress and inflammation in injured neurons and also can increase the functionality of the PI3K/Akt/mTOR axis which results in restoring BDNF production. Moreover, the conditioned medium has a neuroprotective effect due to containing NT-3, and IL-10, and also the presence of growth factors and immunomodulatory cytokines [66].

In an in vitro study, the immunosuppressive, neuroprotective and anti-apoptotic properties of hPDLSCs-CM obtained from patients with relapsing remitting- MS have been demonstrated. The PDLSC-CM contained extracellular vesicles with anti-inflammatory cytokines (TGF-β and IL-10). Preconditioning of lipopolysaccharide (LPS)-stimulated NSC34 mouse motoneurons with the PDLSCs-CM led to the enhanced level of NFκB and TLR4 and decreased amount of IκB-α in inflammation-exposed motoneurons. Moreover, neuroprotective markers such as nestin, NGF, NFL 70, GAP-43 as well as inflammatory cytokines and apoptotic markers were modulated in this study [67].

In the eye, the neuroprotective factors of hPDLSCs have beneficial effects on degenerated retina and photoreceptor survival, possibly by an anti-apoptotic mechanism. Experiments confirmed that PDLSCs alone exhibited neuroprotective effect and enhanced neurite regeneration in retinal tissue without macrophage...
recruitment. In in vitro experiments, the neuroprotection of PDLSCs can be increased when they are in direct cell–cell with retinal ganglion cells (RGCs) in retinal explant culture. This process increased BDNF secretion by twofold, but the mechanism of this positive feedback needs further investigation [68, 69].

PDLSCs are capable of cell replacement and differentiation into the functional RGCs [12, 54]. The intravitreal transplantation of PDLSCs can promote survival of RGC and regeneration of axons in a rat model of optic nerve injury which implies a potential therapy for neurological diseases via neuroprotection [70].

The differentiated PDLSCs to RGCs expressed markers related to neurons and RGCs including β-III tubulin, POU4F2, ATOH7, MAP2, TAU, SIX3 and NEUROD1 and have the ability to form synapses. They showed spontaneous electrical activities as well as glutamate-induced calcium responses which are the characteristics of functional neurons. During the induction process, the expressions of VEGF and PTEN as miRNA-targeted candidates were significantly upregulated [69].

Moreover, the PDLSCs can be induced to retinal fate expressing photoreceptor makers [68]. PDLSCs produced neurospheres in low attachment culture and express neural progenitor markers. On a surface with Matrigel coating, neurospheres showed rosette-like outgrowth and expressed eye-related factors; 94% of the cells tested positive for Pax6 (retinal progenitor marker). They produced markers of photoreceptors such as rhodopsin, and its kinase and Nrl; also, they showed considerable excitatory glutamate response after continuous induction. Induction into retinal fate was carried out by a protocol to development of retinogenesis and anterior neural plate through inhibition of BMP and Wnt signaling [68, 71].

The PDLSCs have intrinsic PAX6 expression which is mostly located inside of the cytoplasm. After induction to retinal fate, in the majority of cells Pax6 protein was translocated into the nucleus. Pax6 nucleocytoplasmic translocation and also its nuclear retention are mediated by TGFβ signaling and interaction of Smad3-SPARC [72–74]. However, it is not yet to be determined whether the reason of Pax6 translocation is the changes of the retinogenesis signaling or is due to other factors.

**Peripheral nerve system treatment**

PDLSCs through the expression of several neural growth and differentiation factors have shown important neurotrophic effects in peripheral nerve injury [41] (Fig. 4). A
promising strategy for peripheral nerve repair is Schwann cell (SC) transplantation. PDLSCs are one of the cell sources that can be differentiated into SC-like cells [50, 75]. Different pathways are involved in this process, but it is demonstrated that Erk1/2 signaling is one of the most important pathways in the differentiation process of PDLSCs to SCs. During this process, Erk1/2 signaling inhibition leads to reduced expression of SCs specific markers such as P75, S100 and GFAP as well as decreased myelinization-related genes including P0, krox-20 and Oct-6 [76–78].

Reports demonstrated that indirect co-culturing of heterogenous Schwann cells and PDLSCs can induce PDLSCs toward Schwann cell phenotype through allogenic neurotrophic factors released by Schwann cells. Neural differentiation began 24 h after co-culture, and the most detectable neural differentiation of PDLSCs appeared 14 days later [75].

In a study, the biological behavior of induced PDLSCs into Schwann cells (SC) was investigated on the sand-blasted and acid-etched titanium surface. The goal of this study was to seek whether the SC-like cells placed on the implant can replace SCs in injured nerve endings. They used PDLSCs instead of SCs due to difficulties obtaining pure and ample sources of SCs. The study showed that the differentiated PDLSCs had the highest expression of SC markers and proteins on the SA titanium surface [79].

Furthermore, SH-SY5Y cells of human neuroblastoma were incubated with CM of the SCAPs, PDLSCs and DPSCs. Neurotrophic factors in the conditioned medium of these stem cells can induce differentiation of neuroblastoma SH-SY5Y cells to cells with neurites outgrowth. Stimulation of these cells with a combination of growth factors leads to a significant upregulation of GDNF and BDNF in the CM of SCAPs and DPSCs but not in the PDLSCs. Their CM leads to an increase in the length of the neurite and also the number of cells producing neurites. BDNF in their CM plays a vital role in the stimulation of neurite outgrowth [41, 80]. In in vivo, conduits seeded with SCAPs, DPSCs, PDLSCs and rat Schwann cells (rSC) were utilized to treat a 10-mm nerve defect in a rat model of sciatic nerve injury. The greatest distance of axon regeneration was created in rSC and SCAP-treated group. All seeded conduits significantly reduced the expression of caspase-3 in injured area compared to group with empty conduit. In vivo assay detected BDNF expression in the area of the injected cells. All of these stem cells significantly increased axon regeneration and led to neuroprotective effects in neurons of the dorsal root ganglia [41]. The ability of these three stem cells in combination with a fibrin glue conduit showed that SCAP and PDLSCs have neural repair potential through direct differentiation toward neural cells or they participate in nerve regeneration through paracrine manner [70, 80, 81]. A higher level of neuronal markers was detected in PDLSCs and SCAP compared to DPSCs based on mRNA levels and immunocytochemical staining [82].

Moreover, PDLSCs were transplanted into rats with the crush injury in left mental nerve. Concurrently, control group received autologous SCs and PBS. After 5 days of injection, expression of NGF receptor was significantly increased, and after 2 and 4 weeks, the sensory function of the cells was significantly recovered. Also, the numbers of myelinated axons and sensory neurons were significantly amplified. These results demonstrated that the effectiveness of PDLSCs injection for axonal regeneration was equivalent to reparative ability of Schwann cells. Moreover, human PDLSCs through differentiation into Schwann cells can be alternative source for the autologous SCs in order for the regeneration of the peripheral nerve injury [80, 81].

**Main challenges and future perspectives**

Periodontal ligament stem cells can be an appealing source of stem cells for regenerative medicine, including nerve regeneration. Using PDLSCs presents a difficulty in terms of isolation and culturing approaches. It is necessary to investigate the unique culturing procedure required for neuronal differentiation. These cells are heterogeneous sources with various differentiation priorities for multiple cell fates; identifying the precise subgroup of these cells could be a significant step. It is necessary to develop the most efficient methodology for obtaining and storing PDLSC-conditioned media containing various neurotrophic and anti-inflammatory factors. Based on their neurogenic potential, the protein content of the conditioned media of these stem cells has to be investigated further. The effect of their exosome on neural differentiation has yet to be determined. Although significant in vitro and in vivo investigations were carried out in order for neural differentiation of these cells into diverse types of neurons, more preclinical and clinical studies are needed to elucidate their therapeutic potential for neurodegenerative diseases.

**Conclusion**

Periodontal ligament stem cells have favorable biological features that can be obtained from the periodontal ligament as an autologous source. They are readily available, stable, and sufficient sources of cells that do not trigger immunological responses and have great features such as immune modulation and neuroprotection. PDLSCs are a unique type of cell that can be used in repairing neural tissue since they are originated from neural crest. They have potential to differentiate into various cells such as neural-like cells under inductive conditions. Various
compounds in their conditioned media and extracellular vesicles can replace cells in most tasks, but it needs further research into their potential usage. PDLCSCs can release neurotrophic factors which can help in the myelination and the regeneration of neurons. In vitro and in vivo investigations have reported that they are useful in treating central and peripheral nervous system diseases. Furthermore, when paired with biomaterials, PDLCSCs could have significant potential for use in clinical investigations for neural tissue repair, which has to be investigated further. To summarize, these cells have a good potential for use in clinical investigations for neural regeneration, but there are still a number of challenges to conquer.

Abbreviations
PDLCSCs: Periodontal ligament stem cells; MSCs: Mesenchymal stem cells; BBB: Blood–brain barrier; GMSCs: Gingival MSCs; DFSC: Dental follicle stem cells; SCAP: Stem cells from apical papilla; DPSCs: Dental pulp stem cells; SHED: Stem cells from exfoliated deciduous teeth; CNGCs: Cranial neural crest-derived ectomesenchymal cells; PDL: Periodontal ligament; AD: Alzheimer’s disease; SCI: Spinal cord injury; HBMGCs: Human bone marrow mesenchymal stem cells; bFGF: Basic fibroblast growth factor; IGF-1: Insulin-like growth factor-1; NGF: Nerve growth factor; EGF: Epidermal growth factor; NCSCs: Neural crest stem cells; OA: Okadaic acid; MS: Multiple sclerosis; CM: Conditioned medium; PDLCSCs-CM: PDLCSCs conditioned medium; EAE: Autoimmune encephalomyelitis; LPS: Lipopolysaccharide; RGCs: Retinal ganglion cells; SC: Schwann cell; rSC: Rat Schwann cells.

Acknowledgements
This study was a part of Ph.D. thesis of Fariba Mohebichamkhorami.

Author contributions
All authors made substantial contributions to the conception or design of the work. FM had the idea for the article, performed the literature search and was a major contributor in writing the manuscript. RF, ZN, MA, SKN and SG assisted in writing the paper and drafted the figures. HZ revised the work critically for intellectual content, and all authors read and approved the final manuscript.

Funding
This study was supported by Vice Chancellor of Research Affairs, Shahid Beheshti University of Medical Sciences (Grant No. 29356).

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
The study was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences (Code NO. IR.SBMU.RETECH.REC.1400.601).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no conflict of interest.

Author details
1Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3Department of Cognitive Neuroscience, Institute for Cognitive Science Studies, Tehran, Iran. 4Department of Biology, Tehran Central Branch, Islamic Azad University, Tehran, Iran. 5Medical Nanotechnology and Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Received: 8 January 2022 Accepted: 2 June 2022
Published online: 21 June 2022

References
1. Gutierrez-Gutierrez G, Sereno M, Miralles A, Casado-Sanz E, Gutierrez-Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol. 2010;12(2):81–91.
2. Fortino VR, Chen RS, Pelaez D, Cheung HS. Neurogenesis of neural crest-derived periodontal ligament stem cells by EGF and bFGF. J Cell Physiol. 2014;229(4):479–88.
3. Mueller BK, Mueller R, Schoemaker H. Stimulating neuroregeneration as a therapeutic drug approach for traumatic brain injury. Br J Pharmacol. 2009;157(5):675–85.
4. Nagappan PG, Chen H, Wang D-Y. Neuroregeneration and plasticity: a review of the physiological mechanisms for achieving functional recovery post-injury. Mil Med Res. 2020;7(1):1–16.
5. Chen J, Chopp M. Neurorestorative treatment of stroke: cell and pharmacological approaches. Neurol Res. 2006;34(4):466–73.
6. Grunwell J, Illes J, Karkazis K. Advancing neuroregenerative medicine: a call for expanded collaboration between scientists and ethicists. Neuroethics. 2009;2(1):13–20.
7. Xiao L, Nasu M. From regenerative dentistry to regenerative medicine: progress, challenges, and potential applications of oral stem cells. Stem Cells Transl Med. 2014;7:89.
8. Sandu N, Momen-Heravi F, Sadr-Eshkevari R, Schaller B. Molecular imaging for stem cell transplantation in neuroregenerative medicine. Neurodegener Dis. 2012;9(2):60–7.
9. Ng TK, Fortino VR, Pelaez D, Cheung HS. Progress of mesenchymal stem cell therapy for neural and retinal diseases. World J Stem Cells. 2014;6(2):111.
10. Cooney DS, Wimmers EG, Ibrahim Z, Grahmmer J, Christensen JM, Brat GA, et al. Mesenchymal stem cells enhance nerve regeneration in a rat sciatic nerve repair and hindlimb transplant model. Sci Rep. 2016;6(1):1–12.
11. Schmidt A, Ladage D, Steingen C, Brixius K, Schinköthe T, Klinz F-J, et al. Mesenchymal stem cells transmigrate over the endothelial barrier. Eur J Cell Biol. 2006;85(11):1179–88.
12. Steingen C, Brenig F, Baumgartner L, Schmidt J, Schmidt A, Bloch W. Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells. J Mol Cell Cardiol. 2008;44(6):1072–84.
13. Galindo LT, Filippo TR, Semedo P, Arza CB, Moreira CM, Camara NO, et al. Mesenchymal stem cell therapy modulates the inflammatory response in experimental traumatic brain injury. Neurol Res Int. 2011;2011:1–9.
14. Volponi A, Sharpe P. The tooth—a treasure chest of stem cells. Br Dent J. 2013;215(7):353–8.
15. Andrickov CB, Blufstein A, Rausch-Fan X. Immunomodulatory properties of dental tissue-derived mesenchymal stem cells: implication in disease and tissue regeneration. World J Stem Cells. 2019;11(9):604.
16. Li D, Zou X-Y, El-Ayachi I, Romero LO, Yu Z, Iglesias-Linares A, et al. Human dental pulp stem cells and gingival mesenchymal stem cells display action potential capacity in vitro under neurogenic differentiation. Stem cell Rev Rep. 2019;15(1):67–81.
17. Lin NH, Gronthos S, Bartold P. Stem cells and periodontal regeneration. Aust Dent J. 2008;53(2):108–21.
18. Ng TK, Huang L, Cao D, Yip Y-W, Tsang W, Yam GH-F, et al. Cigarette smoking hinders human periodontal ligament–derived stem cell proliferation, migration and differentiation potentials. Sci Rep. 2015;5(1):1–7.
19. Coura G, Garcez R, De Aguilar CM, Alvarez-Silva M, Magini R, Tentin A. Human periodontal ligament: a niche of neural crest stem cells. J Periodontal Res. 2008;43(S):531–6.
20. Huang CC, Pelaez D, Bendala JD, Garcia-Godoy F, Cheung HS. Plasticity of stem cells derived from adult periodontal ligament. Regen Med. 2009;4(6):809–21.

Mohebichamkhorami et al. Stem Cell Research & Therapy (2022) 13:273 Page 12 of 14
62. Rajan TS, Giacoppo S, Diomede F, Ballerini P, Paolantonio M, Marchisio M, et al. The secretome of periodontal ligament stem cells from MS patients protects against EAE. Sci Rep. 2016;6(1):1–16.

63. Yeasmin S, Ceccarelli J, Vigen M, Caron B, Putnam AJ, Tarle SA, et al. Stem cells derived from tooth periodontal ligament enhance functional angiogenesis by endothelial cells. Tissue Eng Part A. 2014;20(7–8):1188–96.

64. Man RC, Sulaiman N, Idrus RBH, Ariffin SHZ, Wahab RMA, Yazid MD. Insights into the effects of the dental stem cell secretome on nerve regeneration: towards cell-free treatment. Stem Cells Int. 2019; https://doi.org/10.1155/2019/4596150.

65. Giacoppo S, Thangavelu SR, Diomede F, Bramanti P, Conti P, Trubiani O, et al. Anti-inflammatory effects of hypoxia-preconditioned human periodontal ligament cell secretome in an experimental model of multiple sclerosis: a key role of IL-37. FASEB J. 2017;31(1):5592–608.

66. Pizzicannella J, Gugliandolo A, Orsini T, Fontana A, Ventrella A, Mazzon E, et al. Engineered extracellular vesicles from human periodontal-ligament stem cells increase VEGF/VEGFR2 expression during bone regeneration. Front Physiol. 2019;10:512.

67. Rajan TS, Giacoppo S, Trubiani O, Diomede F, Piattelli A, Bramanti P, et al. Conditioned medium of periodontal ligament mesenchymal stem cells exert anti-inflammatory effects in lipopolysaccharide-activated mouse motoneurons. Exp Cell Res. 2016;349(1):152–61.

68. Huang L, Liang J, Geng Y, Tsang W-M, Yao X, Jhanji V, et al. Directing human periodontal ligament-derived stem cells to retinal fate. Invest Ophthalmol Vis Sci. 2013;54(6):3965–74.

69. Ng TK, Jhung JS, Choy KW, Cao D, Leung CK, Cheung HS, et al. Transdifferentiation of periodontal-ligament-derived stem cells into retinal ganglion-like cells and its microRNA signature. Sci Rep. 2015;5(1):1–16.

70. Cen LP, Ng TK, Liang JJ, Zhuang X, Yao X, Yan GHF, et al. Human periodontal-ligament-derived stem cells promote retinal-ganglion cell survival and axon regeneration after optic nerve injury. Stem Cells. 2018;36(6):844–55.

71. Kadar K, Kiraly M, Porcsalmy B, Molnar B, Racz G, Blazsek J, et al. Differnetiation potential of stem cells from human dental origin-promise for tissue engineering. J Physiol Pharmacol. 2009;60(Suppl 7):167–75.

72. Girocotti T, Frost V, Maillard M, Johansen T, Wheeler GN, Dawes LJ, et al. The MH1 domain of Smad3 interacts with Pax6 and represses autoregulation of the Pax6 P1 promoter. Nucleic Acids Res. 2007;35(3):890–901.

73. Mu Y, Gudey SK, Landström M. Non-Smad signaling pathways. Cell Tissue Res. 2013;350(1):53–66.

74. Soundararajan P, Fawcett JP, Rafuse VF. Guidance of postural motoneurons requires MAPK/ERK signaling downstream of fibroblast growth factor receptor 1. J Neurosci. 2010;30(19):6595–606.

75. Li X, Liao D, Geng P, Tang H. Neural differentiation of periodontal ligament stem cells induced by neurotrophic Schwann cells factors. Arch Med Sci. 2009;5(3):313.

76. Trubiani O, Pizzicannella J, Caputi S, Marchisio M, Mazzon E, Paganelli R, et al. Periodontal ligament stem cells: current knowledge and future perspectives. Stem cells and development. 2019;28(15):995–1003.

77. Dapeng L, Xiaojie L, Ping G, Yan D, Gang S. Erk1/2 signalling is involved in the differentiation of periodontal ligament stem cells to Schwann cells in dog. Arch Oral Biol. 2014;59(5):487–91.

78. Soundararajan P, Fawcett JP, Rafuse VF. Guidance of postural motoneurons requires MAPK/ERK signaling downstream of fibroblast growth factor receptor 1. J Neurosci. 2010;30(19):6595–606.

79. Xiaojie L, Dapeng L, Ping G, Yan D, Gang S. Biological behavior of neurally differentiated periodontal ligament stem cells on different titanium implant surfaces. J Biomed Mater Res Part A. 2014;102(8):2805–12.

80. Pisciotta A, Bertoni L, Vallarola A, Berti G, Mecugni D, Carnevale G. Neural crest derived stem cells from dental pulp and tooth-associated stem cells for peripheral nerve regeneration. Neural Regen Res. 2020;15(3):373.

81. Li B, Jung H-J, Kim S-M, Kim M-J, Jahng JW, Lee J-H. Human periodontal ligament stem cells repair mental nerve injury. Neural Regen Res. 2013;8(30):2827.

82. Lee J-H, Um S, Song I-S, Kim HY, Seo BM. Neurogenic differentiation of human dental stem cells in vitro. J Korean Assoc Oral Maxillofac Surg. 2014;40(4):173–80.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.